Form 4 for ACET Adicet Bio, Inc.
Accepted 2022-04-05 00:00:00 ET · period of report 2022-04-01 · accession 0001209191-22-023285 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-04-05 | 2022-04-01+ | ACET | Galimi Francesco | SVP, Chief Medical Off | S - Sale+OE | $21.00 | -15.6K | 59.9K | -21% | -$327.6K |
| DM | 2022-04-05 | 2022-04-01+ | ACET | Galimi Francesco | SVP, Chief Medical Off | M - OptEx | $10.03 | +15.6K | 66.0K | +31% | +$156.5K |
| DM | 2022-04-05 | 2022-04-01+ | ACET | Galimi Francesco | SVP, Chief Medical Off | M - OptEx | $0.00 | -15.6K | 74.0K | -17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-01 | S | D | 7,621 | $21.00 | 59,917 | D | — | — | |
| 2 | Common | Common Stock | 2022-04-04 | M | A | 1,775 | $16.82 | 61,692 | D | — | — | |
| 3 | Common | Common Stock | 2022-04-04 | S | D | 168 | $21.00 | 59,917 | D | — | — | |
| 4 | Common | Common Stock | 2022-04-04 | M | A | 168 | $5.97 | 60,085 | D | — | — | |
| 5 | Common | Common Stock | 2022-04-01 | M | A | 7,621 | $5.97 | 67,538 | D | — | — | |
| 6 | Common | Common Stock | 2022-04-04 | S | D | 1,775 | $21.00 | 59,917 | D | — | — | |
| 7 | Common | Common Stock | 2022-04-04 | M | A | 6,036 | $13.27 | 65,953 | D | — | — | |
| 8 | Common | Common Stock | 2022-04-04 | S | D | 6,036 | $21.00 | 59,917 | D | — | — | |
| 9 | Derivative | Employee Stock Option (Right to Buy) | 2022-04-01 | M | D | 7,621 | — | 113,820 | D | $5.97 · — to 2029-10-15 | 7,621 Common Stock | (F3) Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.740 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." (F2) A total of 128,424 shares subject to an employee stock option were received as described in footnote (3). 25% of the shares vested on September 23, 2020, and 1/36th of the remaining unvested shares vest on each of the next thirty-six (36) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting date. |
| 10 | Derivative | Employee Stock Option (Right to Buy) | 2022-04-04 | M | D | 168 | — | 113,652 | D | $5.97 · — to 2029-10-15 | 168 Common Stock | (F3) Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.740 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." (F2) A total of 128,424 shares subject to an employee stock option were received as described in footnote (3). 25% of the shares vested on September 23, 2020, and 1/36th of the remaining unvested shares vest on each of the next thirty-six (36) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting date. |
| 11 | Derivative | Employee Stock Option (Right to Buy) | 2022-04-04 | M | D | 1,775 | $0.00 | 26,625 | D | $16.82 · — to 2031-02-11 | 1,775 Common Stock | (F5) A total of 28,400 shares subject to an employee stock option were granted on February 12, 2021, with 1/48th of the shares vesting on each of the next forty-eight (48) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting dates. |
| 12 | Derivative | Employee Stock Option (Right to Buy) | 2022-04-04 | M | D | 6,036 | $0.00 | 73,964 | D | $13.27 · — to 2031-01-12 | 6,036 Common Stock | (F4) A total of 80,000 shares subject to an employee stock option were granted on January 13, 2021, with 1/48th of the shares vesting on each of the next forty-eight (48) monthly anniversaries thereafter, provided that the Reporting Person remains in continuous service as of the applicable vesting dates. |